TRML logo

Tourmaline Bio (TRML)

Profile

Full Name

Tourmaline Bio, Inc.

Ticker Symbol

TRML

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

May 7, 2021

Indexes

Not included

Website

http://www.tourmalinebio.com

Employees

74

Key Details

Price

$14.93(+5.96%)

Market cap

$383.48M(Small cap)

Last Dividend

$1.51

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$2.89(+67.42% YoY)

PE ratio

-

Next earnings date

May 13, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$14.93
TRML price is $14.93

30-Day Relative Volume

1.13
TRML 30-day relative volume is 1.13

Price Performance

Price Most recent change

+5.96%
TRML price was up +5.96% on Apr 15, 2025

Price YTD change

-26.38%
TRML price is down -26.38% since January 1st

Price 1-year change

-16.41%
TRML price is down -16.41% year-on-year

Price 3-year change

-84.27%
TRML price is down -84.27% over the past 3 years

Price Range

Price All-time high

$198.20
TRML price is currently -92.47% below its historical high of $198.20

Price 3-year low

$8.90
TRML price is currently +67.75% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$383.48M
TRML market capitalization is $383.48 million

Market cap 3-year change

-
TRML market capitalization 3-year change is unknown

Market cap All-time high

$1.17B
TRML market capitalization is currently -67.24% below its historical high of $1.17 billion

Market cap sector rank

65.79%
TRML market capitalization is higher than 65.79% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+0.15%
TRML shares outstanding is up +0.15% year-on-year

Shares Outstanding 3-Year Change

-
TRML shares outstanding 3-year change is unknown

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.77
TRML beta is 0.77

200-day SMA

$19.00
TRML price is currently -21.41% below its 200-day simple moving average

50-day SMA

$14.46
TRML price is currently +3.22% above its 50-day simple moving average

RSI

53.03
TRML 14-day relative strength index is 53.03

Volume

1.13
TRML 30-day relative volume is 1.13

ATR

$1.23
TRML average true range is $1.23

10-day Historical Volatility

79.85%
TRML 10-day historical volatility is 79.85%

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Last Paid Dividend

$1.51
TRML last dividend was $1.51 per share, with an ex-dividend date of October 20, 2023

Next Dividend

-
TRML next dividend has not yet been announced

Dividend per share

Dividend per share

-
TRML annual dividend per share value is unknown

Dividend per share Sector Rank

-
TRML annual dividend per share is unknown

Dividend per share 1-Year Change

-
TRML annual dividend per share 1-year change is unknown

Dividend per share 3-Year Change

-
TRML annual dividend per share 3-year change is unknown

Dividend yield

Dividend yield

-
TRML annual dividend yield value is unknown

Dividend yield Sector Rank

-
TRML annual dividend yield is unknown

Other

Payout ratio

-
TRML annual payout ratio value is unknown

Dividends paid

-
TRML annual dividends paid value is unknown

Free cash flow

-$77.27M
TRML annual free cash flow is -$77.27 million

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
TRML annual revenue value is unknown

Revenue Analysts estimate

$6.67M
TRML annual revenue is currently equal to the consensus analysts' forecast

Revenue 1-year change

-
TRML annual revenue 1-year change is unknown

Revenue Sector rank

-
TRML annual revenue is unknown

EPS

EPS

-$2.89
TRML annual earnings per share is -$2.89

EPS Analysts estimate

-$3.45
TRML annual earnings per share is currently -16.30% lower than the consensus analysts' forecast

EPS 1-year change

+67.42%
TRML annual earnings per share is up +67.42% year-on-year

EPS Sector rank

30.9%
TRML annual earnings per share is higher than 30.9% of companies in Healthcare sector

Profit

Gross profit

-
TRML annual gross profit value is unknown

Gross margin

-
TRML annual gross profit margin value is unknown

Operating profit

-$89.73M
TRML annual operating income is -$89.73 million

Operating margin

-
TRML annual operating profit margin value is unknown

Net income

-$73.21M
TRML annual net profit is -$73.21 million

Net margin

-
TRML annual net profit margin value is unknown

Expenses

Total expenses

$89.73M
TRML annual total expenses is $89.73 million

Operating expenses

$89.73M
TRML annual total operating expenses is $89.73 million

Cost of goods sold

-
TRML annual cost of goods sold value is unknown

Selling, general & administrative expenses

$22.75M
TRML annual SGA is $22.75 million

Depreciation and amortization

$39.00K
TRML annual depreciation & amortization is $39.00 thousand

Interest expense

-
TRML annual interest expense value is unknown

Income tax

-
TRML annual income tax value is unknown

EBIT & EBITDA

EBIT

-$89.73M
TRML annual earnings before interest & taxes is -$89.73 million

EBITDA

-$89.69M
TRML annual EBITDA is -$89.69 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$309.00M
TRML annual total assets is $309.00 million

Non current assets

$40.16M
TRML annual long term assets is $40.16 million

Current assets

$268.84M
TRML annual total current assets is $268.84 million

Cash and cash equivalents

$30.51M
TRML annual cash & cash equivalents is $30.51 million

Accounts receivable

-
TRML annual accounts receivable value is unknown

Inventory

-
TRML annual inventory value is unknown

Liabilities

Total liabilities

$8.95M
TRML annual total liabilities is $8.95 million

Long term liabilities

$40.00K
TRML annual total long term liabilities is $40.00 thousand

Current liabilities

$8.91M
TRML annual total current liabilities is $8.91 million

Accounts payable

$3.58M
TRML annual accounts payable is $3.58 million

Debt

Total debt

$244.00K
TRML annual total debt is $244.00 thousand

Total debt 1-year change

-41.2%
TRML annual total debt is down -41.2% year-on-year

Long term debt

$17.00K
TRML annual long term debt is $17.00 thousand

Short term debt

$227.00K
TRML annual short term debt is $227.00 thousand

Equity & Capital

Shareholders equity

$300.05M
TRML annual stockholders equity is $300.05 million

Book value

$300.05M
TRML annual book value is $300.05 million

Retained earnings

-$135.26M
TRML annual retained earnings is -$135.26 million

Working capital

$259.93M
TRML annual working capital is $259.93 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$77.26M
TRML annual cash flow from operations is -$77.26 million

Cash from operations 1-year change

-175.14%
TRML annual cash flow from operations is down -175.14% year-on-year

Cash from investing

-$194.31M
TRML annual cash flow from investing activities is -$194.31 million

Cash from investing 1-year change

-5160.03%
TRML annual cash flow from investing activities is down -5160.03% year-on-year

Cash from financing

$161.35M
TRML annual cash flow from financing activities is $161.35 million

Cash from financing 1-year change

+2.95%
TRML annual cash flow from financing activities is up +2.95% year-on-year

CAPEX

CAPEX

-
TRML annual capital expenditures value is unknown

CAPEX 1-year change

-
TRML annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$77.27M
TRML annual free cash flow is -$77.27 million

Free cash flow 1-year change

-174.63%
TRML annual free cash flow is down -174.63% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
TRML annual gross profit margin value is unknown

Operating margin

-
TRML annual operating profit margin value is unknown

Net margin

-
TRML annual net profit margin value is unknown

ROA & ROE

ROA

-23.69%
TRML annual return on assets is -23.69%

ROE

-24.40%
TRML annual return on equity is -24.40%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
TRML price to earnings ratio value is unknown

PE ratio Sector rank

-
TRML price to earnings ratio is unknown

PB Ratio

PB ratio

1.28
TRML price to book ratio is 1.28

PB ratio Sector rank

50.78%
TRML price to book ratio is higher than 50.78% of companies in Healthcare sector

PS Ratio

PS ratio

-
TRML price to sales ratio value is unknown

PS ratio Sector rank

-
TRML price to sales ratio is unknown

Enterprise value

Enterprise value

$353.22M
TRML enterprise value is $353.22 million

Enterprise value Sector rank

65.1%
TRML enterprise value is higher than 65.1% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.94
TRML EV/EBITDA is -3.94

EV/EBITDA Sector rank

22.02%
TRML EV/EBITDA is higher than 22.02% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

30.18
TRML annual current ratio is 30.18

Quick ratio

-
TRML annual quick ratio value is unknown

Leverage

Debt to equity

0.00
TRML annual debt to equity ratio is 0.00

Interest coverage ratio

-
TRML annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
TRML piotroski f-score value is unknown

Altman Z-Score

-
TRML altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Mar 14, 25 Wedbush
Outperform
Mar 14, 25 HC Wainwright & Co.
Buy
Mar 6, 25 Wedbush
Outperform
Feb 24, 25 LifeSci Capital
Outperform
Dec 11, 24 HC Wainwright & Co.
Buy
Dec 11, 24 Guggenheim
Buy
Dec 11, 24 Cantor Fitzgerald
Overweight
Dec 6, 24 BMO Capital
Outperform
Nov 11, 24 HC Wainwright & Co.
Buy
Aug 12, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

ABVX logo
ABIVAX SA (ABVX)
CELC logo
Celcuity (CELC)
SANA logo
Sana Biotechnology (SANA)
INNV logo
InnovAge Holding (INNV)
DCTH logo
Delcath Systems (DCTH)
ETON logo
Eton Pharmaceuticals (ETON)
AHG logo
Akso Health (AHG)
ANGO logo
AngioDynamics (ANGO)
PACB logo
Pacific Biosciences of California (PACB)
  • What is the ticker symbol for Tourmaline Bio?
  • Does Tourmaline Bio pay dividends?
  • What sector is Tourmaline Bio in?
  • What industry is Tourmaline Bio in?
  • What country is Tourmaline Bio based in?
  • When did Tourmaline Bio go public?
  • Is Tourmaline Bio in the S&P 500?
  • Is Tourmaline Bio in the NASDAQ 100?
  • Is Tourmaline Bio in the Dow Jones?
  • When was Tourmaline Bio's last earnings report?
  • When does Tourmaline Bio report earnings?
  • Should I buy Tourmaline Bio stock now?

What is the ticker symbol for Tourmaline Bio?

The ticker symbol for Tourmaline Bio is NASDAQ:TRML

Does Tourmaline Bio pay dividends?

No, Tourmaline Bio does not pay dividends

What sector is Tourmaline Bio in?

Tourmaline Bio is in the Healthcare sector

What industry is Tourmaline Bio in?

Tourmaline Bio is in the Biotechnology industry

What country is Tourmaline Bio based in?

Tourmaline Bio is headquartered in United States

When did Tourmaline Bio go public?

Tourmaline Bio's initial public offering (IPO) was on May 7, 2021

Is Tourmaline Bio in the S&P 500?

No, Tourmaline Bio is not included in the S&P 500 index

Is Tourmaline Bio in the NASDAQ 100?

No, Tourmaline Bio is not included in the NASDAQ 100 index

Is Tourmaline Bio in the Dow Jones?

No, Tourmaline Bio is not included in the Dow Jones index

When was Tourmaline Bio's last earnings report?

Tourmaline Bio's most recent earnings report was on Mar 13, 2025

When does Tourmaline Bio report earnings?

The next expected earnings date for Tourmaline Bio is May 13, 2025

Should I buy Tourmaline Bio stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page